These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11806864)

  • 1. Adjunctive high-dose glycine in the treatment of schizophrenia.
    Javitt DC; Silipo G; Cienfuegos A; Shelley AM; Bark N; Park M; Lindenmayer JP; Suckow R; Zukin SR
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):385-91. PubMed ID: 11806864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
    Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Silipo G; Lichtenstein M
    Arch Gen Psychiatry; 1999 Jan; 56(1):29-36. PubMed ID: 9892253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
    Heresco-Levy U; Ermilov M; Lichtenberg P; Bar G; Javitt DC
    Biol Psychiatry; 2004 Jan; 55(2):165-71. PubMed ID: 14732596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
    Potkin SG; Jin Y; Bunney BG; Costa J; Gulasekaram B
    Am J Psychiatry; 1999 Jan; 156(1):145-7. PubMed ID: 9892314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.
    Sumiyoshi T; Jin D; Jayathilake K; Lee M; Meltzer HY
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):451-5. PubMed ID: 15817136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
    Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
    J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Horowitz A; Kelly D
    Br J Psychiatry; 1996 Nov; 169(5):610-7. PubMed ID: 8932891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.
    Neeman G; Blanaru M; Bloch B; Kremer I; Ermilov M; Javitt DC; Heresco-Levy U
    Am J Psychiatry; 2005 Sep; 162(9):1738-40. PubMed ID: 16135636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
    Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
    Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
    Tsai GE; Lin PY
    Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE; Yang P; Chang YC; Chong MY
    Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    Shaw P; Sporn A; Gogtay N; Overman GP; Greenstein D; Gochman P; Tossell JW; Lenane M; Rapoport JL
    Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.